These findings reflect that the expression status of PD-L2 may still affect the clinical efficacy in the absence of PD-1/PD-L1 checkpoint inhibitors, and the prognostic significance of PD-L2 in malignant tumors is still controversial. This evidence concerns the gene PDCD1LG2 and cancer.